Colliers Securities analyst Kyle Bauser reiterated a Buy rating on Senseonics Holdings (SENS) today and set a price target of $4.00. The company’s shares closed last Tuesday at $1.86.
According to TipRanks.com, Bauser is a 3-star analyst with an average return of 5.3% and a 48.3% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Chembio Diagnostics.
Senseonics Holdings has an analyst consensus of Hold, with a price target consensus of $3.17.
See today’s analyst top recommended stocks >>
Based on Senseonics Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.89 million and GAAP net loss of $102 million. In comparison, last year the company earned revenue of $8.95 million and had a GAAP net loss of $35.61 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.
